Evaluating enrollment and representation in COVID-19 and HIV vaccine clinical trials

被引:0
作者
Lezo Ramirez, Daisy [1 ]
Koleske, Emily [1 ]
Ometoruwa, Omolola [1 ]
Park Chang, Jun Bai [1 ]
Kanwal, Urwah [1 ]
Morreale, Nicholas [1 ]
Avila Paz, Andres Alberto [1 ]
Tong, Alexandra [1 ]
Baden, Lindsey R. [1 ,2 ]
Sherman, Amy C. [1 ,2 ]
Walsh, Stephen R. [1 ,2 ]
机构
[1] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02130 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
关键词
clinical trial enrollment; diversity; representation; vaccine; HIV; SARS-CoV-2; HEALTH; MINORITIES; GENDER; SEX;
D O I
10.3389/fpubh.2024.1411970
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Vaccine clinical trials should strive to recruit a racially, socioeconomically, and ethnically diverse range of participants to ensure appropriate representation that matches population characteristics. Yet, full inclusion in research is often limited.Methods A single-center retrospective study was conducted of adults enrolled at Brigham and Women's Hospital (Boston, MA) between July 2020 and December 2021. Demographic characteristics, including age, race, ethnicity, ZIP code, and sex assigned at birth, were analyzed from both HIV and COVID-19 vaccine trials during the study period, acknowledging the limitations to representation under these parameters. We compared the educational attainment of vaccine trial participants to residents of the Massachusetts metropolitan area, geocoded participants' addresses to their census block group, and linked them to reported median household income levels from publicly available data for 2020. Frequency and quartile analyses were carried out, and spatial analyses were performed using ArcGIS Online web-based mapping software (Esri).Results A total of 1030 participants from four COVID-19 vaccine trials (n = 916 participants) and six HIV vaccine trials (n = 114 participants) were included in the analysis. The median age was 49 years (IQR 33-63) and 28 years (IQR 24-34) for the COVID-19 and HIV vaccine trials, respectively. Participants identifying as White were the majority group represented for both the COVID-19 (n = 598, 65.3%) and HIV vaccine trials (n = 83, 72.8%). Fewer than 25% of participants identified as Hispanic or Latin. Based on ZIP code of residence, the median household income for COVID-19 vaccine clinical trial participants (n = 846) was 102,088 USD (IQR = 81,442-126,094). For HIV vaccine clinical trial participants (n = 109), the median household income was 101,266 USD (IQR 75,052-108,832).Conclusion We described the characteristics of participants enrolled for HIV and COVID-19 vaccine trials at a single center and found similitude in geographical distribution, median incomes, and proportion of underrepresented individuals between the two types of vaccine candidate trials. Further outreach efforts are needed to ensure the inclusion of individuals from lower educational and socioeconomic brackets. In addition, continued and sustained efforts are necessary to ensure inclusion of individuals from diverse racial and ethnic backgrounds.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Representation of women in neuropsychology research prior to the COVID-19 pandemic
    Prieto, Sarah
    Bangen, Katherine J.
    Riegler, Kaitlin
    Kim, Stella H.
    Mahmood, Zanjbeel
    Kaseda, Erin T.
    Ellison, Rachael L.
    Sullivan-Baca, Erin
    JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY, 2024, 46 (03) : 173 - 186
  • [32] Vaccine Development against COVID-19: Study from Pre-Clinical Phases to Clinical Trials and Global Use
    Ahmed, Sagheer
    Khan, Saeed
    Imran, Imran
    Al Mughairbi, Fadwa
    Sheikh, Fahad Sultan
    Hussain, Javid
    Khan, Ajmal
    Al-Harrasi, Ahmed
    VACCINES, 2021, 9 (08)
  • [33] Profiles of COVID-19 clinical trials in the Chinese Clinical Trial Registry
    Xu, Peng
    Xing, Xiangyu
    Yu, Keying
    Lv, Zhiguo
    Cui, Huijing
    Shi, Yuhang
    Chang, Tianying
    Zhang, Dongmei
    Zhang, Yibin
    Wang, Kai
    Lu, Jing
    Huang, Qingxia
    Li, Xiangyan
    Cui, Yingzi
    Shi, Li
    Wang, Tan
    Niu, Junqi
    Wang, Jian
    EMERGING MICROBES & INFECTIONS, 2020, 9 (01) : 1695 - 1701
  • [34] Clinical trials and recent progress in HIV vaccine development
    Zubair, Akmal
    Bibi, Bushra
    Habib, Faiza
    Sujan, Arooba
    Ali, Muhammad
    FUNCTIONAL & INTEGRATIVE GENOMICS, 2024, 24 (05)
  • [35] Evaluating the Effects of the COVID-19 Pandemic on HIV Testing, Enrollment, ART Use and Mortality in Suriname Using Interrupted Time Series Analysis
    Stijnberg, Deborah
    McKee, M.
    Commiesie, E.
    Adhin, M.
    Schrooten, W.
    AIDS AND BEHAVIOR, 2025,
  • [36] COVID-19 and HIV
    Paulina Posada-Vergara, Maria
    Carlos Alzate-Angel, Juan
    Martinez-Buitrago, Ernesto
    COLOMBIA MEDICA, 2020, 51 (02):
  • [37] COVID-19 vaccine hesitancy: a midwifery survey into attitudes towards the COVID-19 vaccine
    Funlayo Odejinmi
    Rebecca Mallick
    Christina Neophytou
    Kade Mondeh
    Megan Hall
    Claire Scrivener
    Katie Tibble
    Mary Turay-Olusile
    Nandita Deo
    Doreen Oforiwaa
    Rita Osayimwen
    BMC Public Health, 22
  • [38] COVID-19 vaccine hesitancy: a midwifery survey into attitudes towards the COVID-19 vaccine
    Odejinmi, Funlayo
    Mallick, Rebecca
    Neophytou, Christina
    Mondeh, Kade
    Hall, Megan
    Scrivener, Claire
    Tibble, Katie
    Turay-Olusile, Mary
    Deo, Nandita
    Oforiwaa, Doreen
    Osayimwen, Rita
    BMC PUBLIC HEALTH, 2022, 22 (01)
  • [39] Temporal trends and characteristics associated with racial, ethnic, and sex representation in COVID-19 clinical trials: A systematic review and meta-analysis
    Kaczynski, Matthew
    Vassilopoulos, Athanasios
    Vassilopoulos, Stephanos
    Sisti, Anthony
    Benitez, Gregorio
    Tran, Quynh-Lam
    Mylona, Evangelia K.
    Shehadeh, Fadi
    Rogers, Ralph
    Mylonakis, Eleftherios
    CONTEMPORARY CLINICAL TRIALS, 2024, 143
  • [40] Current Status of COVID-19 (Pre)Clinical Vaccine Development
    Ye, Tingting
    Zhong, Zifu
    Garcia-Sastre, Adolfo
    Schotsaert, Michael
    De Geest, Bruno G.
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2020, 59 (43) : 18885 - 18897